Tavo Biotherapeutics Secures $17 Million Financing for Groundbreaking Ophthalmic Therapies

Tavo Biotherapeutics has recently announced the successful closing of a $17 million Series A financing round, a pivotal step in the advancement of novel therapeutic solutions aimed at glaucoma and retinal diseases. This funding was spearheaded by Pureos Bioventures and included significant contributions from Polaris Partners alongside ongoing support from the existing investor, Tau Capital.

The capital raised in this financing is expected to significantly enhance Tavo’s innovative pipeline, enabling the company to pursue clinical and preclinical development of its flagship therapies, TAV-001 and TAV-002. These groundbreaking treatments are designed to address unmet medical needs within the realm of ophthalmology.

To bolster its leadership, Tavo Biotherapeutics has appointed Dr. Federico Grossi, M.D., Ph.D., as the new Chief Medical Officer. Dr. Grossi brings a wealth of experience from his previous role as Chief Medical Officer at Apellis Pharmaceuticals, where he was instrumental in the clinical development of Syfovre and Empaveli, two FDA-approved therapies. His expertise is set to guide Tavo’s clinical strategy and execution as the company advances its therapeutic offerings in the ophthalmic sector.

In addition to Dr. Grossi’s appointment, Tavo Biotherapeutics is proud to welcome Daniel Bradbury as Chairman of the Board of Directors. With an extensive career spanning over 40 years in the life sciences industry, Bradbury's experience includes leading Amylin Pharmaceuticals to market three pioneering medicines before its acquisition by Bristol-Myers Squibb in 2012. His leadership is expected to foster growth and innovation within Tavo’s operational framework.

The financing round also welcomed two new strategic Board members, Dr. Dominik Escher and Dr. Nil Gural, representing Pureos Bioventures and Polaris Partners, respectively. Their extensive backgrounds in financing and generating innovative therapeutic solutions will further strengthen Tavo’s growth potential.

Gary Berman, the CEO of Tavo Biotherapeutics, expressed his excitement over this funding milestone: "We are thrilled to partner with Pureos and Polaris, and we are grateful for the continued support of Tau Capital. This financing enables us to accelerate the advancement of our programs in glaucoma and retinal disease, where there remains a critical need for new, more effective treatment options."

Dr. Dominik Escher echoed these sentiments, stating, "Tavo has built a compelling pipeline addressing major unmet needs in ophthalmology with differentiated science and a clear clinical development strategy. We believe these programs have the potential to deliver significantly better treatment options for patients. We are excited to lead this financing and support Tavo through its next phase of growth."

Tavo’s primary therapeutic candidates include TAV-001, a disease-modifying topical treatment for glaucoma, which targets the autonomic nervous system to help mitigate inflammation and degeneration associated with the disease. This program will move into Phase 2 clinical trials in the latter part of 2026, marking a significant step forward in glaucoma treatment.

TAV-002, on the other hand, is a bispecific antibody that targets both VEGF and a protein involved in upstream signaling, addressing severe retinal conditions, including various forms of retinal degeneration and diabetes-related complications. The potential of these therapies reveals Tavo Biotherapeutics' commitment to changing the landscape of ophthalmic treatment.

In conclusion, Tavo Biotherapeutics stands at the forefront of innovation in eye care, supported by strategic funding and an experienced leadership team, paving the way for the future of cutting-edge therapies that can transform the patient experience in treating debilitating ocular diseases.